Mylan/Viatris – Recall of insulin glargine (insulin glargine-yfgn)

- On April 12, 2022, Mylan/Viatris announced a consumer-level recall of one lot of insulin glargine (insulin glargine-yfgn) injection, 100 units/mL which is packaged in a 10 mL vial that is inside a carton due to the potential for the label to be missing on some vials. The product information, batch number and expiry date information are present on the carton.

- This recall does not pertain to the branded, interchangeable biosimilar, Semglee® (insulin glargine-yfgn) vial.

- The recalled lots were distributed in the U.S. between December 2021 and March 2022.

Product description	NDC #	Lot #/ Expiration date
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 10 mL vial	49502-393-80	BF21002800 (8/2023)

- Insulin glargine-yfgn is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

- For patients receiving treatment with more than one type of insulin (eg, both short and long-acting insulin), a missing label on insulin glargine-yfgn vials could lead to a mix-up of products/strengths, which may result in less optimal glycemic control (either high or low blood sugar) which could result in serious complications.

- To date, Mylan/Viatris has not received reports of any adverse events or identifiable safety concerns attributed to the product consumed from this lot.

- Patients who have the recalled insulin glargine-yfgn should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled insulin glargine-yfgn.

- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.

- Contact Viatris Customer Relations by phone at **1-800-796-9526** or by email at **customer.service@viatris.com** for more information about the recall. Contact Stericycle at **1-888-912-7084** for return information.